Albireo Pharma develops and commercializes bile acid modulators for the treatment of liver or gastrointestinal diseases and disorders, focusing on pediatric liver diseases. Its commercial offering includes the drug Bylvay, which targets progressive familial intrahepatic cholestasis and is currently in Phase III clinical trials for other pediatric disorders. The company also works on developing drugs A3907 and A2342 for adult liver diseases, supported by a license agreement with EA Pharma Co.